Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients

Bone Marrow Transplant. 2022 Feb;57(2):309-311. doi: 10.1038/s41409-021-01531-3. Epub 2021 Nov 29.

Authors

Christianne Tolêdo de Souza Leal¹, Luciano José Megale Costa², Juliana Pereira³, Fernando Barroso Duarte⁴, Raphael Barros Tavares⁵, Angelo Atalla⁶, Bruna Sousa Sabioni⁷, Abrahão Elias Hallack Neto⁵

Affiliations

¹ Federal University of Juiz de Fora, Juiz de Fora, Brazil. [email protected].
² University of Alabama at Birmingham, EUA, Birmingham, AL, USA.
³ São Paulo University, São Paulo, Brazil.
⁴ Federal University of Ceará, Fortaleza, Brazil.
⁵ Federal University of Juiz de Fora, Juiz de Fora, Brazil.
⁶ Monte Sinai Hospital, Juiz de Fora, Brazil.
⁷ São José Hospital, Teresópolis, Brazil.

PMID: 34845366
DOI: 10.1038/s41409-021-01531-3

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use
Etoposide / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
Lomustine / therapeutic use
Lymphoma* / drug therapy
Neoplasm Recurrence, Local
Transplantation Conditioning
Transplantation, Autologous

Substances

Etoposide
Lomustine
Cyclophosphamide